Indication
Hypertriglyceridemia
Hypertriglyceridemia is a metabolic dyslipidemia defined by elevated fasting serum triglyceride concentrations, conventionally classified as 150 mg/dL or higher. Read more about Hypertriglyceridemia
345 drugs 155 manufacturers
Drugs that treat it
Common Hypertriglyceridemia therapies.
EZALLOR SPRINKLE (rosuvastatin calcium)
LIPITOR (atorvastatin calcium)
ZOCOR (simvastatin)
CADUET (amlodipine besylate/atorvastatin calcium)
LOVAZA (omega-3 acid ethyl esters)
LIPOFEN (fenofibrate)
CADUET (amlodipine besylate/atorvastatin calcium)
ATORVALIQ (atorvastatin calcium)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonHypertriglyceridemia is a metabolic dyslipidemia defined by elevated fasting serum triglyceride concentrations, conventionally classified as 150 mg/dL or higher.
Affecting pediatric and adult populations, the condition stems from primary genetic mutations in lipid metabolism or secondary factors, including obesity, poorly controlled type 2 diabetes mellitus, excessive alcohol intake, and specific pharmacotherapies.
Pathophysiologically, it results from increased hepatic synthesis of very-low-density lipoproteins, impaired peripheral clearance of triglyceride-rich lipoproteins via lipoprotein lipase, or a combination of both.
While mild-to-moderate elevations primarily accelerate atherogenesis and heighten the risk of atherosclerotic cardiovascular disease, severe elevations—typically exceeding 500 to 1,000 mg/dL—significantly increase the clinical risk of acute pancreatitis.
- nih.gov
Hypertriglyceridemia is a metabolic dyslipidemia defined by elevated fasting serum triglyceride concentrations, conventionally classified as 150 mg/dL or higher Affecting pediatric and adult populations, the condition stems from primary genetic mutations in lipid metabolism or secondary factors, including obesity, poorly controlled type 2 diabetes mellitus, excessive alcohol intake, and specific pharmacotherapies While mild-to-moderate elevations primarily accelerate atherogenesis and heighten t...
- nih.gov
Affecting pediatric and adult populations, the condition stems from primary genetic mutations in lipid metabolism or secondary factors, including obesity, poorly controlled type 2 diabetes mellitus, excessive alcohol intake, and specific pharmacotherapies Pathophysiologically, it results from increased hepatic synthesis of very-low-density lipoproteins, impaired peripheral clearance of triglyceride-rich lipoproteins via lipoprotein lipase, or a combination of both
- nih.gov
Pathophysiologically, it results from increased hepatic synthesis of very-low-density lipoproteins, impaired peripheral clearance of triglyceride-rich lipoproteins via lipoprotein lipase, or a combination of both
- nih.gov
While mild-to-moderate elevations primarily accelerate atherogenesis and heighten the risk of atherosclerotic cardiovascular disease, severe elevations—typically exceeding 500 to 1,000 mg/dL—significantly increase the clinical risk of acute pancreatitis
- nih.gov
While mild-to-moderate elevations primarily accelerate atherogenesis and heighten the risk of atherosclerotic cardiovascular disease, severe elevations—typically exceeding 500 to 1,000 mg/dL—significantly increase the clinical risk of acute pancreatitis
Personalize your experience
Follow Hypertriglyceridemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.